TargetMol

Abiraterone Acetate

Product Code:
 
TAR-T6215
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6215-10mg10mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6215-1mL1 mL * 10 mM (in DMSO)£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6215-50mg50mg£119.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6215-100mg100mg£134.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6215-500mg500mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Abiraterone acetate is an androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.
CAS:
154229-18-2
Formula:
C26H33NO2
Molecular Weight:
391.555
Pathway:
Metabolism
Purity:
0.9989
SMILES:
CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1
Target:
P45

References

Zhang X, Cheng L, Gao C, et al.Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-?B Activation in T Cells and Suppressing Anti-Tumor Immunity.Cancer Research.2023 Li R, et al. Clin Cancer Res. 2012, 18(13), 3571-3579. Duc I, et al. J Steroid Biochem Mol Biol. 2003, 84(5), 537-542. Pinto-Bazurco Mendieta MA, et al. J Med Chem. 2008, 51(16), 52009-52018. Rice M A, Kumar V, Tailor D, et al. SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer. Cell Reports Medicine. 2022: 100502. Richards J, et al. Cancer Res. 2012, 72(9), 2176-2182.